Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management

Christie M. Ballantyne, Deepak L. Bhatt, Christopher P. Cannon, Sergio Fazio, Marc S. Sabatine

    Research output: Contribution to journalArticle

    Abstract

    This CME-accredited CME Snapshot seven-part series is intended for interventional cardiologists, other cardiologists, lipidologists, endocrinologists, and other diabetologist physicians involved in the ongoing management of patients with persistent hypercholesterolemia. During these activities, expert faculty will participate in a series of interactive discussions on the latest evidence and their clinical experience managing patients with persistently elevated low-density lipoprotein cholesterol levels using nonstatin lipid-lowering medications, including inhibitors of the enzyme protein convertase subtilisin or kexin type 9 (PCSK9). (Online access: https://lipidsnapshotcme.elsevierresource.com/.)

    Original languageEnglish (US)
    JournalAmerican Journal of Cardiology
    DOIs
    StateAccepted/In press - Jan 1 2018

    Fingerprint

    Subtilisin
    Hypercholesterolemia
    Enzyme Inhibitors
    LDL Cholesterol
    Proteins
    Physicians
    Lipids
    Cardiologists
    Endocrinologists

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine

    Cite this

    Raising the Bar by Lowering the Target : Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management. / Ballantyne, Christie M.; Bhatt, Deepak L.; Cannon, Christopher P.; Fazio, Sergio; Sabatine, Marc S.

    In: American Journal of Cardiology, 01.01.2018.

    Research output: Contribution to journalArticle

    Ballantyne, Christie M. ; Bhatt, Deepak L. ; Cannon, Christopher P. ; Fazio, Sergio ; Sabatine, Marc S. / Raising the Bar by Lowering the Target : Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management. In: American Journal of Cardiology. 2018.
    @article{f2ed65b2d2b246f6958319cee2d98a27,
    title = "Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management",
    abstract = "This CME-accredited CME Snapshot seven-part series is intended for interventional cardiologists, other cardiologists, lipidologists, endocrinologists, and other diabetologist physicians involved in the ongoing management of patients with persistent hypercholesterolemia. During these activities, expert faculty will participate in a series of interactive discussions on the latest evidence and their clinical experience managing patients with persistently elevated low-density lipoprotein cholesterol levels using nonstatin lipid-lowering medications, including inhibitors of the enzyme protein convertase subtilisin or kexin type 9 (PCSK9). (Online access: https://lipidsnapshotcme.elsevierresource.com/.)",
    author = "Ballantyne, {Christie M.} and Bhatt, {Deepak L.} and Cannon, {Christopher P.} and Sergio Fazio and Sabatine, {Marc S.}",
    year = "2018",
    month = "1",
    day = "1",
    doi = "10.1016/j.amjcard.2018.08.020",
    language = "English (US)",
    journal = "American Journal of Cardiology",
    issn = "0002-9149",
    publisher = "Elsevier Inc.",

    }

    TY - JOUR

    T1 - Raising the Bar by Lowering the Target

    T2 - Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management

    AU - Ballantyne, Christie M.

    AU - Bhatt, Deepak L.

    AU - Cannon, Christopher P.

    AU - Fazio, Sergio

    AU - Sabatine, Marc S.

    PY - 2018/1/1

    Y1 - 2018/1/1

    N2 - This CME-accredited CME Snapshot seven-part series is intended for interventional cardiologists, other cardiologists, lipidologists, endocrinologists, and other diabetologist physicians involved in the ongoing management of patients with persistent hypercholesterolemia. During these activities, expert faculty will participate in a series of interactive discussions on the latest evidence and their clinical experience managing patients with persistently elevated low-density lipoprotein cholesterol levels using nonstatin lipid-lowering medications, including inhibitors of the enzyme protein convertase subtilisin or kexin type 9 (PCSK9). (Online access: https://lipidsnapshotcme.elsevierresource.com/.)

    AB - This CME-accredited CME Snapshot seven-part series is intended for interventional cardiologists, other cardiologists, lipidologists, endocrinologists, and other diabetologist physicians involved in the ongoing management of patients with persistent hypercholesterolemia. During these activities, expert faculty will participate in a series of interactive discussions on the latest evidence and their clinical experience managing patients with persistently elevated low-density lipoprotein cholesterol levels using nonstatin lipid-lowering medications, including inhibitors of the enzyme protein convertase subtilisin or kexin type 9 (PCSK9). (Online access: https://lipidsnapshotcme.elsevierresource.com/.)

    UR - http://www.scopus.com/inward/record.url?scp=85058432901&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85058432901&partnerID=8YFLogxK

    U2 - 10.1016/j.amjcard.2018.08.020

    DO - 10.1016/j.amjcard.2018.08.020

    M3 - Article

    AN - SCOPUS:85058432901

    JO - American Journal of Cardiology

    JF - American Journal of Cardiology

    SN - 0002-9149

    ER -